Do you need to test your new therapeutic drugs on robust ex-vivo models via Histoculture Drug Response Assays ?
The relevance of some models can be sometimes questioned because the heterogeneity of tumors for example is not recreated. We have a solution!
Use our new ex-vivo histoculture protocols to explore directly on patient-derived models the effect of your new therapeutic drugs : the perfect model for clinical simulation studies.
Based on Histoculture Drug Response Assays (HDRA), this AnyGenes® service is perfect to:
You can discover all our catalog of signaling pathways and its characteristics by clicking here.
All Histoculture Drug Response Assays (HDRA) experiments and data analysis are performed on our high-throughput molecular platform to get you very robust results in a very short time! You just have to send us your biopsies according to our strict recommended conditions in order to guarantee the quality of each sample and experiment.
Bibliography:
Yoon YS et al. Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer. Anticancer Res. 2017 Mar;37(3):1297-1303.
Delyon et al. Validation of a preclinical model for assessment of drug efficacy in melanoma. Oncotarget. 2016 Mar 15; 7(11): 13069–13081.
Jung PS et al. Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution. Anticancer Res. 2013 Mar;33(3):1029-1034.